Axsome Therapeutics, Inc. (AXSM)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

12 annual periodsNewest to oldest
202520242023202220212020201920182017201620152014
Revenue$638.5M$385.7M$270.6M$50.0M
Research & development$183.3M$187.1M$97.9M$57.9M$58.1M$70.2M$53.6M$23.5M$20.0M$21.2M$6.8M$4.3M
Operating expenses$124.7M$99.1M$67.2M$32.8M$27.2M$27.5M$9.2M$5.7M
Operating income−$166.8M−$280.6M−$231.8M−$179.8M−$124.7M−$99.1M−$67.2M−$32.8M−$27.2M−$27.5M−$9.2M−$5.7M
EBITDAderived−$159.9M−$273.6M−$225.0M−$175.4M
Net income−$183.2M−$287.2M−$239.2M−$187.1M−$130.4M−$102.9M−$68.3M−$31.0M−$28.9M−$27.2M−$12.2M−$6.0M
Basic EPSper diluted share-$3.68-$5.99-$5.27-$4.60-$3.47-$2.77-$2.01-$1.15-$1.27-$1.42-$1.02-$0.66
Diluted EPSper diluted share-$3.68-$5.99-$5.27-$4.60-$3.47-$2.77-$2.01-$1.15-$1.27-$1.42-$1.02-$0.66

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys3$200.5K disclosed value
Sells (SEC code S)60$162.20M disclosed value
63 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jun 11, 2026Form 4 · 10b5-1JEFFS ROGERDirectorSellCommon Stock286$249.12$71.2K58.4K
Jun 10, 2026Form 4 · 10b5-1JEFFS ROGERDirectorSellCommon Stock286$246.18$70.4K58.7K
Jun 10, 2026Form 4 · 10b5-1Mahony SusanDirectorSellCommon Stock300$246.18$73.9K829
Jun 10, 2026Form 4 · 10b5-1Coleman MarkDirectorSellCommon Stock643$249.00$160.1K30.4K
Jun 9, 2026Form 4 · 10b5-1Mahony SusanDirectorSellCommon Stock300$237.21$71.2K1.1K